The OPTRELL Mapping Catheter with TRUEref Technology. Credit: Biosense Webster/PRNewswire.

Biosense Webster, a part of Johnson and Johnson MedTech, has introduced the OPTRELL Mapping Catheter with TRUEref Technology in the US.

Last year, the company secured 510(k) clearance from the US Food and Drug Administration for this mapping catheter.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Powered by the CARTO3 System, the high-density diagnostic catheter comes with small electrodes placed in a fixed array formation for delivering high-definition electrophysiological mapping of complex cardiac arrhythmia cases.

The arrhythmia cases include ventricular tachycardia, atrial tachycardia, persistent atrial fibrillation (AFib) and redo AFib ablation.

Featuring 48 electrodes that are symmetrically distributed across and along six splines, the new device is powered by the CARTO3 System and offers intelligent insights and high-resolution directional mapping.

The CARTO3 System provides local conduction vectors, which show the real-time direction and speed of the electrical impulses travelling through the heart.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, with tight electrode spacing and small electrodes, the mapping catheter can generate higher signal resolution for improved maps of the heart.

Biosense Webster president Jasmina Brooks said: “The OPTRELL Mapping Catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO 3 mapping system, to diagnose and treat arrhythmias.

“This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients.”

The company also plans to commercially launch the OPTRELL Mapping Catheter with TRUEref Technology in Japan later this year.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact